Navigation Links
Systagenix Announces Formation of New Global Medical Advisory Board to Support Future Clinical Advances in Wound Care

LONDON, October 13 /PRNewswire/ -- Systagenix Wound Management has announced the formation of a new global Medical Advisory Board, consisting of a group of multi-disciplinary and highly respected wound care clinicians and practitioners from North America and Europe, which will be led by Systagenix's newly appointed Medical Director, Dr Robert Snyder.

Representing major specialist organisations and thought leaders in the wound care field, the Systagenix Medical Advisory Board will meet at specific intervals to provide feedback, input and guidance on company clinical and commercial strategies and their implementation. The group represents a broad section of the wound care clinical community with multi-disciplinary backgrounds, including academic and health economic experts, practicing surgeons, and nurse specialists. As well as advising Systagenix regarding their existing portfolio, they will focus on new and emerging technologies as well as future clinical trends within wound care. They will also advise on other critical issues, such as health economics and reimbursement in order to help Systagenix meet the changing needs of the global wound care market.

In addition to clinical and new product development, working with Dr Snyder, the Systagenix Medical Advisory Board will also focus on education, including new pathways to help reach and communicate with fellow healthcare professionals on the best and most up-to-date wound care practices.

Systagenix was formed by a management buyout of the Johnson & Johnson Professional Wound Care business which had a 75 year heritage. Systagenix has very clear objectives to become the world's strongest and most admired wound care company. The new Medical Advisory Board is designed to help the company meet those objectives by better understanding the needs of the clinician and their patients.

Systagenix's CEO, Steve Atkinson comments: "Education, innovation and forward thinking are crucial in the constantly changing and evolving wound care field. We are delighted to welcome such a prestigious panel of experts under the renowned guidance of Dr Snyder, all of whom will help us define and refine our thinking for future clinical, educational and technological developments."

Dr Snyder adds: "With such a varied and experienced panel of experts, we are bound to create new and exciting opportunities to forge ahead with innovation which is specifically aimed at meeting clinician and patient needs around the world. I am delighted that the Systagenix Medical Advisory Board has been formed and I look forward to working with the group as we seek to pioneer new ideas and techniques in wound care across a number of key areas".

Notes to Editors:

Members of the Systagenix Clinical Advisory Board are:

Chair: Dr. Robert Snyder, DPM, CWS: Medical Director, Systagenix; Diplomat, American Board of Podiatric Surgery; Fellow, American College of Food & Ankle Surgery; Certified Wound Specialist; Medical Director, Wound Healing Centre, University Hospital, Tamarac, Florida; Clinical Professor (Adjunct), Temple University College of Podiatric Medicine; Diplomat, American Academy of Wound Management; serves on the board of directors, Association for the Advancement of Wound Care

Professor David G. Armstrong, DPM, PhD: Professor of Surgery (with Tenure), University of Arizona; co-founded the Southern Arizona Limb Salvage Alliance; founder and co-chair of the International Diabetic Food Conference

Professor Dr. Med. Matthias Augustin: Professor for Health Economics & QoL Research Group, Department of Dermatology, University Clinics of Hamburg, Germany

Mona M. Baharestani, PhD, ANP, CWOCN, CWS: Associate Professor & Secretary for the Advancement of Wound Care, Center for Nursing Research, East Tennessee State University, USA; Faculty Professor, Oxford University Wound Healing Summer School, UK

Laura Bolton, PhD: Adjunct Associate Professor of the Department of Surgery, Bioengineering Section, New Jersey, USA; member of Editorial Boards of Wound Repair and Regeneration, Ostomy/Wound Management, Advances in Skin & Wound Care & WOUNDS publications; co-chairs the Association for the Advancement of Wound Care Guideline Department

Pr. Frank Duteille, MD: Head of Department of Plastic Reconstructive and Esthetic Surgery, University Hospital, Nantes, France

Dieter Mayer, MD: Vascular Surgeon, EBSQ-VASC, FMH; Senior Consultant of Vascular Surgery & Head of Wound Care, Zurich University Hospital, Switzerland

Zena Moore, PhD, MSc, FFNMRCSI, PG Dip, RGN: Lecturer in Wound Healing & Tissue Repair & Research Methodology, Faculty of Nursing & Midwifery, Royal College of Surgeons in Ireland; Current President of European Wound Management Association and chair of the education committee

Prof. Marco Romanelli, MD, PhD: Consultant Dermatologist, Department of Dermatology, University of Pisa, Italy; Director Wound Healing Research Unit, University of Pisa; leads a research group actively involved in clinical, laboratory and educational activities

Dr Thomas E. Serena, MD, FACS, FACHM, FAPWCA: Founder & Medical Director of Pennsylvania North Centers for Advanced Wound Care, USA; founder of the NewBridge Medical Research Corporation and emeritus member of the Board of Director of the Wound Healing Society

Prof. Gary Sibbald, BSc, MD, FRCPC (Med) (Derm), ABIM, DABD, MEd: Professor of Public Health Sciences and Medicine, University of Toronto; Director of medical education for Women's College Hospital and Chair of the faculty of Medical Education Committee; Board member and President of the Canadian Association of Continuing Health Education, University of Toronto, Canada

Dot Weir, RN, CWON, CWS: Director of Wound Care for Osceola Regional Medical Center, Florida, USA; held posts of Treasurer & President of Association for Advancement of Wound Care

Thomas Wild, MD: Department of Surgery, University of Vienna, Austria; President Elect of Austrian Wound Association

Systagenix Portfolio Details

Professional Advanced Wound Care Products:

ACTISORB(R) Activated Charcoal Dressing with Silver - helps to manage infection through its unique mode of action that traps and kills bacteria and eliminates malodors. The first commercialized silver dressing available at the time of its launch in 1980. The safety and efficacy of ACTISORB(R) Dressings is now supported with published clinical evidence in over 13,000 patients.

ADAPTIC(R) Non-Adhering Dressing - helps to protect regenerating tissue and minimizes patient pain and trauma during dressing changes.

INADINE(R) PVP-I Non-Adherent Dressing - a topical wound dressing impregnated with an ointment containing 10% povidone iodine is indicated for the management of ulcerative wounds and may also be used for the prevention of infection in minor burns and minor traumatic skin loss injuries

NU-GEL(R) Hydrogel with Alginate - a transparent hydro active amorphous gel containing sodium alginate creates a moist wound-healing environment, which assists with natural autolytic debridement and desloughing of wounds.

PROMOGRAN(R) Matrix Dressing - a unique, clinically proven combination of collagen and oxidized regenerated cellulose ("ORC"); facilitates tissue granulation through modulation of the wound environment.

PROMOGRAN PRISMA(TM) Balancing Matrix Dressing - combines collagen and ORC with an optimal level of silver; helps restore the normal wound-healing environment by reducing bacterial levels without causing harm to host cells.

REGRANEX(R) (becaplermin) Gel 0.01% - a gel containing recombinant human platelet derived growth factor; the first and only growth factor approved for clinical use in the U.S. and Europe to heal and close lower extremity diabetic neuropathic ulcers.

SILVERCEL(R) Anti-microbial Alginate Dressing - provides a controlled, balanced and sustained release of silver that helps manage infection and exudates while offering superior dressing tensile strength for easy, intact removal.

TIELLE(R) Hydropolymer Dressings - a broad range of foam dressings handling different levels of exudates to reduce wound maceration and leakage while optimizing cost effectiveness through increased dressing wear time.

Professional General Wound Care Products:

TOPPER(R) Drain Swab and TOPPER(R) Non-Woven Fabric Swab - a unique rayon/polyester, non-woven sponge that provides improved strength, absorbency, and scrubbing texture compared to traditional gauze.

RELEASE(R) Low-Adherent Dressing - utilizes a unique perforated film design that directs exudates away from the wound; minimizes discomfort and tissue damage during dressing changes.

REGAL(R) Filmated Non-Woven Swab - a multi-layer absorbent swab covered with a film of viscose fibers to disperse exudates and to provide enhanced absorption capability.

About Systagenix

Systagenix Wound Management was formed by a management buyout of the Johnson & Johnson Professional Wound Care business which had a 75 year heritage. Systagenix aims to become the world's strongest and most admired wound care company. The business has the history and knowledge, and a new, dynamic, energetic and highly informed management team to take it to the next level in the UK and across the globe.

Systagenix manufactures in excess of 30 million wound dressings a month. These are used to treat patients in hospitals, nursing homes and also in their own homes in over 50 countries. Some of the products are used to treat acute wounds in surgery and accidents, where they are used to protect against infection and encourage the wound to heal naturally, while other products, and this is where Systagenix's reputation has been forged and revered, is in advanced wound care, where the business has created products that actively promote healing in some of the most challenging wounds that result from chronic conditions such as diabetes, obesity and vascular disease. It is in these situations that Systagenix's products are used to save patients from limb amputation.

For more information:

Contact Susan Leigh or Gilllian Waddell on +44-(0)207-498-8211 or

SOURCE Systagenix

SOURCE Systagenix
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results
Post Your Comments:
(Date:11/24/2015)... Malaysia , Nov. 24, 2015  Asia-Pacific ... contract research organisation (CRO) market. The trend of ... in lower margins but higher volume share for ... capacity and scale, however, margins in the CRO ... Organisation (CRO) Market ( ), finds ...
(Date:11/24/2015)... , ... November 24, 2015 , ... ... healthy metabolism. But unless it is bound to proteins, copper is also toxic ... (NIH), researchers at Worcester Polytechnic Institute (WPI) will conduct a systematic study of ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... This fall, ... at competitive events in five states to develop and pitch their BIG ideas to ... from each state are competing for votes to win the title of SAP's Teen ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... that the remaining 11,000 post-share consolidation (or 1,100,000 ... (the "Series B Warrants") subject to the previously ... November 23, 2015, which will result in the ... effect to the issuance of such shares, there ...
Breaking Biology Technology:
(Date:11/9/2015)... 2015 ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition ... Market 2015-2019" report to their offering. ... ) has announced the addition of ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... -- Daon, a global leader in mobile biometric authentication ... version of its IdentityX Platform , IdentityX v4.0. ... have already installed IdentityX v4.0 and are seeing ... UAF certified server component as an option and ... These customers include some of the largest and most ...
Breaking Biology News(10 mins):